NCT05348772View on ClinicalTrials.gov

A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions
COVID-19
Interventions
DRUG

AmnioPul-02

Mesenchymal stem / stromal cells, MSC

Trial Locations (1)

21428

Infection clinic, Malmo

Sponsors

Lead Sponsor

Amniotics AB
All Listed Sponsors
lead

Amniotics AB

INDUSTRY

NCT05348772 - A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI | Biotech Hunter | Biotech Hunter